Fennec Pharmaceuticals Inc (FENC)
7.12
+0.14
(+2.01%)
USD |
NASDAQ |
May 16, 16:00
7.11
-0.01
(-0.14%)
After-Hours: 20:00
Fennec Pharmaceuticals Enterprise Value: 210.61M for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 210.61M |
| May 15, 2024 | 206.82M |
| May 14, 2024 | 216.58M |
| May 13, 2024 | 289.20M |
| May 10, 2024 | 281.89M |
| May 09, 2024 | 272.94M |
| May 08, 2024 | 268.88M |
| May 07, 2024 | 271.05M |
| May 06, 2024 | 264.00M |
| May 03, 2024 | 267.79M |
| May 02, 2024 | 264.00M |
| May 01, 2024 | 264.00M |
| April 30, 2024 | 266.44M |
| April 29, 2024 | 265.36M |
| April 26, 2024 | 267.25M |
| April 25, 2024 | 265.90M |
| April 24, 2024 | 263.46M |
| April 23, 2024 | 268.07M |
| April 22, 2024 | 271.86M |
| April 19, 2024 | 270.78M |
| April 18, 2024 | 277.01M |
| April 17, 2024 | 280.53M |
| April 16, 2024 | 295.71M |
| April 15, 2024 | 297.60M |
| April 12, 2024 | 301.94M |
| Date | Value |
|---|---|
| April 11, 2024 | 311.15M |
| April 10, 2024 | 306.82M |
| April 09, 2024 | 312.78M |
| April 08, 2024 | 311.15M |
| April 05, 2024 | 307.36M |
| April 04, 2024 | 313.32M |
| April 03, 2024 | 309.53M |
| April 02, 2024 | 315.49M |
| April 01, 2024 | 311.42M |
| March 28, 2024 | 319.01M |
| March 27, 2024 | 318.06M |
| March 26, 2024 | 312.78M |
| March 25, 2024 | 315.76M |
| March 22, 2024 | 309.70M |
| March 21, 2024 | 317.00M |
| March 20, 2024 | 317.00M |
| March 19, 2024 | 315.38M |
| March 18, 2024 | 317.00M |
| March 15, 2024 | 286.44M |
| March 14, 2024 | 288.06M |
| March 13, 2024 | 285.36M |
| March 12, 2024 | 280.49M |
| March 11, 2024 | 273.73M |
| March 08, 2024 | 278.74M |
| March 07, 2024 | 277.39M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
45.43M
Minimum
Jun 12 2019
323.34M
Maximum
Dec 28 2023
172.37M
Average
166.60M
Median
Nov 27 2020
Enterprise Value Benchmarks
| Pfizer Inc | 220.93B |
| OptiNose Inc | 224.83M |
| NovaBay Pharmaceuticals Inc | 5.209M |
| Palatin Technologies Inc | 23.43M |
| iBio Inc | 16.17M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.682M |
| Revenue (Quarterly) | 9.735M |
| Total Expenses (Quarterly) | 11.62M |
| EPS Diluted (Quarterly) | -0.10 |
| Gross Profit Margin (Quarterly) | 92.96% |
| Profit Margin (Quarterly) | -27.55% |
| Earnings Yield | -8.57% |
| Normalized Earnings Yield | -8.549 |